Literature DB >> 27959628

Signaling and Immune Regulation in Melanoma Development and Responses to Therapy.

William M Lin1, David E Fisher1,2.   

Abstract

Melanoma is a complex and genomically diverse malignancy, and new genes and signaling pathways involved in pathogenesis continue to be discovered. Mechanistic insights into gene and immune regulation in melanoma have led to the development of numerous successful and innovative pharmacologic agents over recent years. Multiple targeted therapies and immunotherapies have already entered the clinic, becoming new standards of care and transforming the prognosis for many patients with malignant melanoma. In this review, we provide an overview of the current understanding of signaling and immune regulation in melanoma and implications for responses to treatment, organized in the framework of hallmark characteristics in cancer.

Entities:  

Keywords:  genomics; immunotherapy; melanocytes; pathogenesis; targeted therapy

Mesh:

Year:  2016        PMID: 27959628     DOI: 10.1146/annurev-pathol-052016-100208

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  13 in total

1.  Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Authors:  Susanne Kaesler; Florian Wölbing; Wolfgang Eberhard Kempf; Yuliya Skabytska; Martin Köberle; Thomas Volz; Tobias Sinnberg; Teresa Amaral; Sigrid Möckel; Amir Yazdi; Gisela Metzler; Martin Schaller; Karin Hartmann; Benjamin Weide; Claus Garbe; Hans-Georg Rammensee; Martin Röcken; Tilo Biedermann
Journal:  JCI Insight       Date:  2019-10-03

Review 2.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

3.  A Novel Pyroptosis-Related lncRNA Signature for Predicting the Prognosis of Skin Cutaneous Melanoma.

Authors:  Jiaheng Xie; Haobo Li; Liang Chen; Yuan Cao; Yiming Hu; Zhechen Zhu; Ming Wang; Jingping Shi
Journal:  Int J Gen Med       Date:  2021-10-08

4.  NEAT1 in bone marrow mesenchymal stem cell-derived extracellular vesicles promotes melanoma by inducing M2 macrophage polarization.

Authors:  Yemei Yang; Shengfang Ma; Zi Ye; Yushi Zheng; Zhenjiong Zheng; Xiongshan Liu; Xianyi Zhou
Journal:  Cancer Gene Ther       Date:  2022-02-03       Impact factor: 5.854

5.  Prognostic factors for postoperative survival in melanoma patients with bone metastasis.

Authors:  Yucheng Wang; Shihong Ren; Xiaokang Gong; Jiacheng Wang; Ning Zhu; Danyang Cai; Jianwei Ruan
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

6.  Long Non-Coding RNA CD27-AS1-208 Facilitates Melanoma Progression by Activating STAT3 Pathway.

Authors:  Jingjing Ma; Qiong Shi; Sen Guo; Peng Xu; Xiuli Yi; Yuqi Yang; Weigang Zhang; Yu Liu; Lin Liu; Qiao Yue; Tao Zhao; Tianwen Gao; Weinan Guo; Chunying Li
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

7.  Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma.

Authors:  Qihang Zhao; Qiang Wang; Tengjiao Wang; Junfang Xu; Tingting Li; Qiuyan Liu; Qinghua Yao; Pin Wang
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

8.  ImmReg: the regulon atlas of immune-related pathways across cancer types.

Authors:  Tiantongfei Jiang; Weiwei Zhou; Zhenghong Chang; Haozhe Zou; Jing Bai; Qisen Sun; Tao Pan; Juan Xu; Yongsheng Li; Xia Li
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

9.  NEAT1/miR-200b-3p/SMAD2 axis promotes progression of melanoma.

Authors:  Wen-Jie Zhou; Hao-Yu Wang; Jie Zhang; Hai-Ying Dai; Zhi-Xian Yao; Zhong Zheng; Sun Meng-Yan; Ke Wu
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

10.  A Novel Autophagy-Related lncRNA Gene Signature to Improve the Prognosis of Patients with Melanoma.

Authors:  Yi Ding; Tian Li; Min Li; Tuersong Tayier; MeiLin Zhang; Long Chen; ShuMei Feng
Journal:  Biomed Res Int       Date:  2021-06-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.